Onxeo Announces its Financial Agenda for 2021

Paris (France), January 7, 2021 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced its financial agenda for 2021.


Event Date*
Full-year 2020 results Tuesday, March 30, 2021
Shareholders’ general meeting Wednesday, May 12, 2021
Half-year 2021 results Wednesday, July 28, 2021


* This preliminary agenda may be modified. Press releases are published after financial markets close.


Download the press release in .pdf format